Published in Gut on July 01, 1998
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med (2000) 4.98
Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet (1992) 3.33
Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med (2001) 2.56
Low prevalence of SPINK1 gene mutations in adult patients with chronic idiopathic pancreatitis. J Med Genet (2001) 2.55
Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet (2001) 2.39
Regulation of gastric epithelial cell growth by Helicobacter pylori: offdence for a major role of apoptosis. Gastroenterology (1997) 2.39
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther (2013) 2.21
Endoscopic closure of esophageal intrathoracic leaks: stent versus endoscopic vacuum-assisted closure, a retrospective analysis. Endoscopy (2013) 2.08
A sonographically guided technique for central venous access. AJR Am J Roentgenol (1997) 2.05
Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet (1994) 2.05
[Prospective Epidemiologic Study of Epigastric Discomfort (PRESTO). Ground work and preliminary results]. Dtsch Med Wochenschr (1999) 2.01
Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa. Gut (1999) 1.97
Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut (2001) 1.97
Mutations of the cystic fibrosis gene, but not cationic trypsinogen gene, are associated with recurrent or chronic idiopathic pancreatitis. Am J Gastroenterol (2000) 1.90
Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol (1998) 1.89
Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat (2008) 1.85
Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol (1997) 1.83
Association between fulminant hepatic failure and a strain of GBV virus C. Lancet (1996) 1.82
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol (2010) 1.76
Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut (2002) 1.74
Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol (1997) 1.70
Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy (2006) 1.70
CFTR and its key role in in vivo resting and luminal acid-induced duodenal HCO3- secretion. Acta Physiol (Oxf) (2008) 1.65
Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J (2003) 1.64
CREB controls LAP/C/EBP beta transcription. Mol Cell Biol (1997) 1.62
Incidence and prognostic value of malnutrition and wasting in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.62
Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol (1997) 1.61
Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol (2004) 1.60
Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology (1996) 1.53
[S3-guideline colorectal cancer version 1.0]. Z Gastroenterol (2013) 1.51
Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. J Clin Virol (2007) 1.51
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer (2005) 1.51
Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol (1997) 1.49
A mass in the eye. Lancet (2002) 1.46
Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem (1998) 1.45
Structural organization of the hepatitis B virus minichromosome. J Mol Biol (2001) 1.45
Keratin 8 Y54H and G62C mutations are not associated with inflammatory bowel disease. Dig Liver Dis (2004) 1.45
Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy (1996) 1.44
Effects of cyclosporine on human dendritic cell subsets. Transplant Proc (2005) 1.43
[Diagnosis of autoimmune hepatitis]. Med Klin (Munich) (1999) 1.40
Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology (2001) 1.38
Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol (1999) 1.38
ESPEN Guidelines on Enteral Nutrition: Geriatrics. Clin Nutr (2006) 1.37
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut (2005) 1.34
The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy. J Hepatol (1998) 1.34
Interleukin 6 and liver regeneration. Gut (2000) 1.32
Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol (1999) 1.31
Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol Cell Biol (2001) 1.31
Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol (2001) 1.31
Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J Biol Chem (1997) 1.31
Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology (2000) 1.30
Concanavalin A-induced liver cell damage: activation of intracellular pathways triggered by tumor necrosis factor in mice. Gastroenterology (1998) 1.28
GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis (1998) 1.27
Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology (1996) 1.27
Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology (1996) 1.26
Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol (2004) 1.25
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. Z Gastroenterol (2011) 1.24
Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. Hepatology (2000) 1.24
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol (1997) 1.24
Interleukin-6-induced tethering of STAT3 to the LAP/C/EBPbeta promoter suggests a new mechanism of transcriptional regulation by STAT3. J Biol Chem (2000) 1.23
Expression of leptin and leptin receptor isoforms in the human stomach. Gut (2000) 1.22
Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology (1997) 1.21
Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat (2007) 1.21
ESPEN Guidelines on Enteral Nutrition: Pancreas. Clin Nutr (2006) 1.20
The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther (2013) 1.19
Chronic hepatitis e in heart transplant recipients. Am J Transplant (2012) 1.18
Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl (2000) 1.18
NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration. Am J Physiol Gastrointest Liver Physiol (2000) 1.18
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat (2006) 1.17
Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res (1997) 1.17
Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol (1998) 1.17
Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem (2000) 1.16
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology (1999) 1.15
IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A (1999) 1.15
Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology (1998) 1.14
A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology (1997) 1.13
Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat (2006) 1.12
Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut (2002) 1.12
Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer (2008) 1.12
The Na+/H+ exchanger isoform 2 is the predominant NHE isoform in murine colonic crypts and its lack causes NHE3 upregulation. Am J Physiol Gastrointest Liver Physiol (2004) 1.12
Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut (2005) 1.11
Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) (2001) 1.10
Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut (1999) 1.10
Hepatitis C and autoimmune hepatitis. Hepatology (2000) 1.10
Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J (1999) 1.10
Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV infection. Virology (1991) 1.10
Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelial migration and barrier function. Am J Physiol (1997) 1.09
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother (2001) 1.09
Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther (2004) 1.09
Telomere shortening of epithelial cells characterises the adenoma-carcinoma transition of human colorectal cancer. Gut (2003) 1.09